Henderson State University launches aviation courses for non-degree-seeking pilots
The aviation flight training program, turning into the Arkansas Aviation Academy, is more than a name change. It expands flight education beyond those enrolled at the school.
New Arkansas law creates incentives for alternative aviation fuel
Three courses are now open to non-degree students. They include a commercial multi-engine add-on course, a tailwheel course, and a Certified Flight Instructor spin-training course.
They are available only to people who already have a commercial pilot certificate. Shannon Clardy, Henderson State University Dean of the College of Aviation, Science, and Nursing, said the 16-plane fleet allows more room for advanced training.
'That's what we're focused on right now. As our fleet capacity grows, then our offerings will also grow,' Clardy said.
It also fills a hiring need in the aviation industry.
'That is all experience that pilots will need to move out into industry, whether they are flying charter airplanes, flying freight, or flying passengers,' Clardy explained.
United Airlines wants to turn algae into jet fuel
Taylor Scalzi went from student to instructor. She completed the commercial multi-engine add-on courses last week.
'It really broadens my horizons of where I can go, and what I can do,' Scalzi explained.
Each of the three initial courses can be completed in less than a week. Accommodations will be available on campus for participating pilots during their week-long training. Scalzi said she is excited to see who the academy brings in.
'It is a very dynamic group. It could be anybody from 18 years old to in their 50s. It doesn't matter,' Scalzi said.
The creation of an aviation advisory board is underway, and the academy is working on alumni connections, along with pursuing potential partnerships with airlines, which could help with landing a job.
Chad Cocroft is a junior HSU aviation major. He said the course is his 'next step' in achieving his dream of becoming a career pilot.
'I enjoy it. I want to do it for the rest of my life,' Cocroft said.
University of Central Arkansas celebrates groundbreaking of Aviation Academy hangar
Henderson's long-established professional pilot bachelor's degree program is the only public university program of its kind in the state. For additional information, visit or call (870) 230-5585 to schedule training.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ASX Penny Stocks To Watch In August 2025
Australian shares are poised for a modest rise, closing out the week with a slight advance, as investors remain largely unfazed by recent economic events and global market fluctuations. Despite this subdued backdrop, the allure of penny stocks persists, offering potential opportunities for those willing to explore beyond established names. Although the term "penny stocks" may seem outdated, it still captures the essence of investing in smaller or newer companies that could provide significant value when backed by strong financial health. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.445 A$127.53M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.39 A$112.74M ★★★★★★ GTN (ASX:GTN) A$0.405 A$77.22M ★★★★★★ IVE Group (ASX:IGL) A$2.99 A$461M ★★★★★☆ West African Resources (ASX:WAF) A$2.77 A$3.16B ★★★★★★ Regal Partners (ASX:RPL) A$3.12 A$1.05B ★★★★★★ Bravura Solutions (ASX:BVS) A$1.925 A$862.98M ★★★★★★ Austco Healthcare (ASX:AHC) A$0.37 A$135.23M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$4.62 A$219.22M ★★★★★★ CTI Logistics (ASX:CLX) A$1.82 A$146.59M ★★★★☆☆ Click here to see the full list of 451 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. Emeco Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Emeco Holdings Limited offers rental services for surface and underground mining equipment, along with complementary equipment and mining services in Australia, with a market cap of A$478.48 million. Operations: Emeco Holdings' revenue is primarily derived from its Rental segment, which generated A$579.43 million, and its Workshops segment, contributing A$292.97 million. Market Cap: A$478.48M Emeco Holdings Limited presents a compelling case among penny stocks with its strong financial health. The company trades at a significant discount to its estimated fair value and has demonstrated high-quality earnings. Its debt management is robust, with interest payments well-covered by EBIT and operating cash flow covering 84.3% of debt. The net debt to equity ratio stands at a satisfactory 26%, reflecting prudent financial handling, while short-term assets exceed short-term liabilities. However, the board's inexperience and low return on equity may pose challenges. Recent conference presentations highlight ongoing engagement with stakeholders and potential growth initiatives. Navigate through the intricacies of Emeco Holdings with our comprehensive balance sheet health report here. Gain insights into Emeco Holdings' future direction by reviewing our growth report. MFF Capital Investments Simply Wall St Financial Health Rating: ★★★★★★ Overview: MFF Capital Investments Limited is an investment firm manager with a market capitalization of A$2.68 billion. Operations: MFF Capital Investments Limited does not report specific revenue segments. Market Cap: A$2.68B MFF Capital Investments stands out in the penny stock arena with its robust financial health, boasting no debt and substantial short-term assets of A$2.9 billion that comfortably cover both short and long-term liabilities. Trading at a significant discount to its estimated fair value, MFF offers high-quality earnings despite a slight decline in revenue and net income over the past year. The company maintains stable weekly volatility and delivers a reliable 3.49% dividend yield. However, recent negative earnings growth contrasts with its strong five-year profit trajectory, while return on equity remains below the desired threshold. Click here to discover the nuances of MFF Capital Investments with our detailed analytical financial health report. Explore historical data to track MFF Capital Investments' performance over time in our past results report. Strickland Metals Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Strickland Metals Limited is an Australian company focused on the exploration of mineral resources, with a market cap of A$339.35 million. Operations: Strickland Metals Limited has not reported any revenue segments. Market Cap: A$339.35M Strickland Metals presents a complex picture in the penny stock landscape. The company is pre-revenue, with less than A$1 million in revenue, and remains unprofitable with increasing losses over the past five years. Despite being debt-free and having short-term assets of A$14.4 million that exceed both its short and long-term liabilities, Strickland faces challenges with a cash runway of less than one year if current free cash flow trends persist. The management team and board are relatively inexperienced, averaging 1.2 years in tenure, while recent significant insider selling may raise concerns about internal confidence in future prospects. Dive into the specifics of Strickland Metals here with our thorough balance sheet health report. Examine Strickland Metals' earnings growth report to understand how analysts expect it to perform. Next Steps Access the full spectrum of 451 ASX Penny Stocks by clicking on this link. Ready For A Different Approach? These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EHL ASX:MFF and ASX:STK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Merck KGaA ventures into new territory in the US
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Merck KGaA has been making new moves to propel itself into becoming what CEO Belén Garijo described as a 'globally diversified science and technology powerhouse.' Most recently, the company closed its $3.4 billion acquisition of Pfizer spinout SpringWorks Therapeutics, which will help it stake a claim in the rare tumor space. And in general, it's all about 'doubling down' on R&D and building the company's U.S. footprint, said Miguel Fernández Alcalde, president of EMD Serono, Merck KGaA's healthcare business in the U.S. and Canada. Germany-based Merck KGaA has undergone a number of transformations throughout its deep history. In 2022, the company restructured into three distinct business units including one focused on the life sciences sector and manufacturing services. But with the contract manufacturing blitz of the COVID-19 pandemic era fading, the company is refocusing. EMD Serono relocated its U.S. headquarters to Boston's Seaport district to place itself squarely in the thick of the region's most innovative 'biotechs, startups, academia and scientists,' Fernández Alcalde said. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization." Miguel Fernández Alcalde President, EMD Serono Merck KGaA also elevated its global head of R&D and chief medical officer of its healthcare business, Dr. Danny Bar-Zohar, to healthcare CEO. 'That tells you that the company's moving along in the direction of doubling down on R&D,' Fernández Alcalde said. Fernández Alcalde's appointment to president of EMD Serono in December is also part of the company's overall quest to build its U.S. footprint and bolster R&D through external deals. 'I want to make sure we are bringing the U.S. [business] to the next level in terms of contributions to the whole organization,' he said. 'I do think we have lots of opportunities in the U.S. ecosystem and U.S. market. My job and my vision and ambition is to really untap all those things that we have ahead of us.' A pharmacist by trade, Fernández Alcalde has been with Merck KGaA since 2014, serving most recently as EMD Serono's chief operating officer. 'That gave me a lot of knowledge and understanding of the business of the company in the States and the teams, the dynamics, the culture, but also the U.S. [healthcare] ecosystem,' he said. Driving dealmaking Central to Fernández Alcalde's role is supplementing the company's current pipeline through external innovation investments, including more strategic in-licensing and co-development opportunities. The SpringWorks acquisition put the company on track to generate at least 50% of its future launch assets from external companies, compared to roughly 10%-15% just 18 months ago. 'It's easily a fivefold increase in our ambition from external innovation,' Fernández Alcalde said. In terms of what kinds of deals they're targeting, Fernández Alcalde said several factors are at play. 'We are not looking [for] the $40 billion type of acquisition,' he said. Nor will they chase first-in-class potential blockbusters with never-explored mechanisms of action. Instead, they'll target smaller deals with the 'right risk balance' for their pipeline. He pointed to the SpringWorks acquisition as an example, which not only adds two FDA-approved drugs to its portfolio, but also a 'runway of three to five years of nice growth' in the form of several clinical-phase pipeline candidates. 'These areas where we have deep, good science [and a] validated proof of concept or an about-to-be-validated proof of concept where the mechanism of action is already validated, is something we are interested in,' he said. The company will take a similar approach when it comes to therapeutic areas by branching out within reason. 'We are not sticking to the [therapeutic areas] we have today, but we are not going to go wild, either,' he said. Rather, they'll look for specialties that are 'adjacent' and 'logical' in terms of what they've been historically known for, such as oncology and neurology/immunology. Again, he pointed to the SpringWorks acquisition as an example and noted that some might ask what track record EMD Serono or Merck KGaA has in rare tumors. 'The answer is zero. But we do know how to commercialize,' he said. Plus, 'it's in an adjacent area of oncology.' Fernández Alcalde is also thinking globally, intending to follow good science wherever it leads and consider deals from around the world. 'We couldn't care less about where that science is coming from, whether it's China, my home country Spain, the U.S. or South Africa,' he said. 'If we think that science will help patients … we will definitely think about it.' Recommended Reading Let's make a deal? Big Pharma execs express varying views on their M&A future
Yahoo
2 days ago
- Yahoo
August 2025's Promising Penny Stocks In Global Market
As global markets navigate a landscape marked by interest rate adjustments and shifting trade dynamics, investors are keenly observing the opportunities that arise amidst these changes. Penny stocks, often seen as relics of earlier market days, still hold relevance by offering exposure to smaller or newer companies with potential for growth. By identifying those with strong financials and promising outlooks, investors can find compelling opportunities in this segment of the market. Top 10 Penny Stocks Globally Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.39 A$109.91M ★★★★★★ Lever Style (SEHK:1346) HK$1.47 HK$915.41M ★★★★★★ GTN (ASX:GTN) A$0.405 A$74.36M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.49 HK$2.1B ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.60 SEK269.95M ★★★★★★ MGB Berhad (KLSE:MGB) MYR0.505 MYR298.78M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.88 SGD11.33B ★★★★★☆ Zetrix AI Berhad (KLSE:ZETRIX) MYR0.90 MYR6.92B ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.155 £183.58M ★★★★★★ Netgem (ENXTPA:ALNTG) €0.934 €31.5M ★★★★★★ Click here to see the full list of 3,784 stocks from our Global Penny Stocks screener. Let's uncover some gems from our specialized screener. Goldpac Group Simply Wall St Financial Health Rating: ★★★★★★ Overview: Goldpac Group Limited is an investment holding company that offers embedded software, secure payment products, and smart financial self-service kiosks in Mainland China and internationally, with a market cap of HK$918.61 million. Operations: The company's revenue is derived from two main segments: Platform and Service, generating CN¥472.94 million, and Embedded Software and Secure Payment Products, contributing CN¥622.36 million. Market Cap: HK$918.61M Goldpac Group Limited, with a market cap of HK$918.61 million, is experiencing challenges as its revenue and profit are expected to decline by 10%-20% and 20%-30% respectively for the first half of 2025 compared to the previous year. Despite being debt-free and having high-quality earnings, the company's return on equity is low at 2.5%, and its profit margins have decreased from last year's figures. The management team is experienced with an average tenure of nine years, but recent board changes may impact strategic direction. The stock trades significantly below estimated fair value but faces unstable dividend records. Dive into the specifics of Goldpac Group here with our thorough balance sheet health report. Assess Goldpac Group's previous results with our detailed historical performance reports. ValueMax Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ValueMax Group Limited, with a market cap of SGD729.63 million, operates in Singapore focusing on pawnbroking, moneylending, jewelry and watches retailing, and gold trading businesses. Operations: There are no specific revenue segments reported for the company. Market Cap: SGD729.63M ValueMax Group Limited, with a market cap of SGD729.63 million, reported strong half-year earnings growth, with sales reaching SGD 268.34 million and net income at SGD 48.03 million, both up from the previous year. Despite high-quality earnings and improved profit margins (19.3%), the company's operating cash flow remains negative, impacting debt coverage and dividend sustainability (3.44%). While its short-term assets significantly exceed liabilities, indicating solid liquidity management, ValueMax's net debt to equity ratio is high at 126.2%. The stock trades below fair value estimates but benefits from experienced management and board teams. Take a closer look at ValueMax Group's potential here in our financial health report. Learn about ValueMax Group's historical performance here. Huapont Life SciencesLtd Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Huapont Life Sciences Co., Ltd. operates in the fields of medicine, medical care, agrochemicals, new materials, and tourism both in China and internationally with a market cap of CN¥8.74 billion. Operations: Huapont Life Sciences Co., Ltd. has not reported specific revenue segments, but it operates across various sectors including medicine, medical care, agrochemicals, new materials, and tourism both domestically and internationally. Market Cap: CN¥8.74B Huapont Life Sciences Co., Ltd., with a market cap of CN¥8.74 billion, operates across diverse sectors but remains unprofitable, facing challenges in earnings growth and profitability. The management team is experienced, with an average tenure of 11.6 years, and the board also brings seasoned expertise. Despite its financial struggles, the company has managed to reduce its debt to equity ratio from 82.6% to 59.7% over five years and maintains satisfactory net debt levels at 31.6%. Recent changes include amendments to company bylaws and the election of Zhang Songshan as a non-independent director. Get an in-depth perspective on Huapont Life SciencesLtd's performance by reading our balance sheet health report here. Understand Huapont Life SciencesLtd's track record by examining our performance history report. Seize The Opportunity Gain an insight into the universe of 3,784 Global Penny Stocks by clicking here. Searching for a Fresh Perspective? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3315 SGX:T6I and SZSE:002004. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
